Optimal Strategies for Managing Adverse Events with CAR-T Therapy in Multiple Myeloma : Episode 2

Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach

June 5, 2024

By Beth Faiman, PhD, CNP
Louis Williams, MD

Opinion

Video

Experts on multiple myeloma discuss how they educate and prepare patients who are going to receive CAR T-cell therapy and provide clinical insights on transitioning patients to community practices following treatment.

EP: 1.Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy

Now Viewing

EP: 2.Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach

EP: 3.Patient Profile 1: Managing CRS Following CAR T-Cell Therapy

EP: 4.Underlying Mechanisms and Signs of CRS

EP: 5.Strategies to Manage or Mitigate CRS

EP: 6.Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy

EP: 7.Clinical Practices for Treating ICANS Following CAR T-Cell Therapy

EP: 8.The Importance of Multidisciplinary Collaboration in CRS Management

EP: 9.Supportive Care Strategies for CAR T-Cell Therapy Recipients

EP: 10.Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy

EP: 11.Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM

Video content above is prompted by the following questions:

How do you prepare patients who are going to receive CAR T-cell therapy? What are you telling them?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!